← Back to Screener
Delcath Systems Inc (DCTH)
Price$10.67
Value ScoreD
Growth ScoreB
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)2.07%
Price vs S&P 500 (4W)-7.05%
VGM Score55.07
Market Capitalization$368.35M
P/E Ratio (Annual)136.42x
All Metrics
P/CF (Annual)16.36x
Book Value / Share (Quarterly)$3.27
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)215.27%
Cash Flow / Share (Quarterly)$0.56
Price vs S&P 500 (YTD)-2.51%
Gross Margin (TTM)85.97%
Net Profit Margin (TTM)0.62%
EPS (TTM)$0.01
10-Day Avg Trading Volume0.49M
EPS Excl Extra (TTM)$0.01
Revenue Growth (5Y)120.10%
EPS (Annual)$0.07
ROI (Annual)2.43%
Gross Margin (Annual)86.16%
Net Profit Margin (5Y Avg)-887.88%
Cash / Share (Quarterly)$2.59
P/E Basic Excl Extra (TTM)656.59x
Revenue Growth QoQ (YoY)26.33%
P/E Normalized (Annual)136.42x
ROA (Last FY)2.18%
Revenue Growth TTM (YoY)67.95%
EBITD / Share (TTM)$-0.03
ROE (5Y Avg)-132.44%
Operating Margin (TTM)-1.79%
Cash Flow / Share (Annual)$0.60
P/B Ratio3.27x
P/B Ratio (Quarterly)2.84x
Net Income / Employee (Annual)$17,300
EV / Revenue (TTM)3.62x
Net Interest Coverage (TTM)-32.13x
ROA (TTM)0.46%
EPS Growth QoQ (YoY)-64.06%
EV / EBITDA (TTM)364.18x
EPS Incl Extra (Annual)$0.07
Current Ratio (Annual)10.92x
Quick Ratio (Quarterly)10.01x
3-Month Avg Trading Volume0.43M
52-Week Price Return-36.75%
EV / Free Cash Flow (Annual)15.60x
P/E Incl Extra (TTM)656.59x
Revenue / Employee (TTM)$579,700
Tangible BV / Share (Quarterly)$1.26
P/S Ratio (Annual)4.32x
Asset Turnover (Annual)0.69x
52-Week High$17.35
Operating Margin (5Y Avg)-763.03%
EPS Excl Extra (Annual)$0.07
CapEx CAGR (5Y)14.68%
26-Week Price Return10.00%
Quick Ratio (Annual)9.69x
13-Week Price Return17.51%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.24x
Enterprise Value$327.03M
Revenue / Share Growth (5Y)30.28%
Asset Turnover (TTM)0.74x
Revenue / Employee (Annual)$546,400
Inventory Turnover (Annual)1.37x
Pretax Margin (Annual)4.12%
Cash / Share (Annual)$2.62
3-Month Return Std Dev38.64%
Gross Margin (5Y Avg)78.86%
Net Income / Employee (TTM)$3,600
ROE (Last FY)2.43%
Net Interest Coverage (Annual)-65.17x
EPS Basic Excl Extra (Annual)$0.07
P/FCF (TTM)19.19x
Receivables Turnover (TTM)6.44x
EV / Free Cash Flow (TTM)17.04x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.01
Receivables Turnover (Annual)7.53x
ROI (TTM)0.51%
P/S Ratio (TTM)4.07x
Pretax Margin (5Y Avg)-887.69%
Revenue / Share (Annual)$2.14
Tangible BV / Share (Annual)$-0.58
Price vs S&P 500 (52W)-61.12%
P/E Ratio (TTM)656.59x
Year-to-Date Return5.64%
5-Day Price Return0.66%
EPS Normalized (Annual)$0.07
ROA (5Y Avg)-87.52%
Net Profit Margin (Annual)3.17%
Month-to-Date Return-1.02%
Cash Flow / Share (TTM)$-3.60
EBITD / Share (Annual)$0.02
Operating Margin (Annual)0.77%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)17.40x
ROI (5Y Avg)-82.27%
P/E Excl Extra (TTM)656.59x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.01
P/TBV (Quarterly)2.67x
P/B Ratio (Annual)3.21x
Inventory Turnover (TTM)1.50x
Pretax Margin (TTM)1.48%
Book Value / Share (Annual)$3.21
Price vs S&P 500 (13W)9.26%
Beta0.55x
P/FCF (Annual)17.57x
Revenue / Share (TTM)$2.51
ROE (TTM)0.51%
52-Week Low$8.12
vGradeD
gGradeB
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.03est. -0.09
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.23
4.23
4.23
4.23
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DCTHDelcath Systems Inc | D | B | C | $10.67 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Delcath Systems develops a drug-device combination for treating primary and metastatic liver cancers. Its proprietary Melphalan Hepatic Delivery System administers high-dose chemotherapy directly to the liver while minimizing systemic exposure and associated side effects. The company manufactures and distributes its products across the United States and Europe.